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Abstract 
Ocular adnexal marginal B-cell lymphoma 
(OAMZL) is the most common type of primary 
lymphoma of this anatomical site. OAMZL is a rare 
entity, accounting for 1-2% of all non-Hodgkin 
lymphomas. A pathogenetic link with chronic 
infection by Chlamydia psittaci has been 
demonstrated in some geographical areas. Because 
of its rarity and the paucity of focused studies the 
clinical management of OAMZL is still 
controversial and uniform guidelines are not 
presently available. 
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Clinics and pathology 
Phenotype/cell stem origin 
The postulated normal counterpart is a post-
germinal centre marginal zone B cell (Swerdlow et 
al., 2016). 
Etiology 
The presence of native lymphoid mucosa associated 
lymphoid tissue (MALT) in the human orbital 
region is still controversial. Some authors described 
this tissue in the lamina propria of the conjunctiva 
and lacrimal drainage system of healthy individuals 
(Knop and Knop, 2000). At a variance with this 
experience, some autoptic studies actually had 
reported MALT only in the context of pathological 
conditions, mostly represented by conjunctivitis 
(Wotherspoon et al., 1994). Following the latter 
hypothesis and in line with some extranodal 
marginal zone lymphomasarising in other 
anatomical sites, a pathogenetic model based on 
chronic antigenic stimulation and acquired genetic 
alterations has been speculated for the occurrence 
of OAMZL.  
In particular, infection by Chlamydia psittaci (Cp) 
has been related to OAMZL, even though with a 
variable geographical distribution (Decaudin et al., 
2008; Ferreri et al., 2008).  
The association between Cp and OAMZL has been 
proved by PCR either on tumoral tissue, 
conjunctival swab and peripheral blood 
mononuclear cells using three different set of 
primers targeting distinct portions of the Cp 
genome and, in selected cases, by laser-assisted 
microdissection (Ponzoni et al., 2008).  
Direct demonstration of the microorganism in the 
cytoplasm of lymphoma-associated macrophages 
by immunohistochemistry has been validated by 
double immunofluorescence and electron 
microscopy besides on ex-vivo cultures (Ferreri et 
al., 2004; Ferreri et al., 2008; Ferreri et al., 2009). 
Another important proof of a significant association 
between Cp and OAMZL is represented by the high 
rate of clinical responses obtained with anti-Cp 
antibiotic treatment (Ferreri et al., 2012).  
A weak association between some autoimmune 
diseases and the development of OAMZL has been 
reported.  
In particular Sjögren disease and autoimmune 
thyroiditis showed a higher risk of periocular 
lymphomas (Wöhrer et al., 2007; Nutting et al., 
2006). A recent study on patients with marginal 
zone lymphomas associated with autoimmune 
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disorders showed a shorter median time to relapse 
and relapse-free survival in patients with 
autoimmune diathesis compared to patients without 
autoimmunity (Kleinstern et al., 2018). 
Epidemiology 
OAMZL is a rare entity accounting for 1-2% of 
non-Hodgkin lymphomas and 8% of all extranodal 
lymphomas with an incidence of about 0.28 person 
for year (Moslehi et al., 2011).  
This lymphoma is usually observed in the 
adulthood, with a median age of about 65 years, 
and a slight female prevalence (Ferry et al., 2007). 
OAMZL is the most common orbital lymphoma, 
(80% of primary cases), followed by follicular 
lymphoma, diffuse large B-cell and mantle cell 
lymphoma (Ferry et al., 2007). 
Clinics 
Clinical presentation depends upon the affected 
anatomical structure: the most common sites are the 
superior anterior orbit (40%) and conjunctiva (35-
40%), followed by the lacrimal gland (10-15%) and 
the eyelids (10%). Bilateral involvement accounts 
in about 10-15% of cases (Ferry et al., 2007; 
Kalogeropoulos et al., 2018).  
OAMZL could be asymptomatic in the early 
phases.  
When symptomatic, it most commonly presents as 
an intraorbital mass or less frequently as a 
conjunctival lesion ("salmon red patch"). Frequent 
signs/symptoms include pain, irritation and 
inflammation (sometimes mimicking 
dacryoadenitis or dacryocystitis), epiphora, 
exophalmos, diplopia, proptosis and loss of vision 
(Ferreri et al., 2008). Since these symptoms are not 
specific, ocular biopsy is essential to achieve a 
definite diagnosis.  
Systemic staging and pre-treatment procedures, 
including bone marrow biopsy, are perfomed.  
In addition to usual procedures, complete peripheral 
blood and biochemical profile as well as 
investigation for infective agents are necessary 
among which Cp, Helicobacter pylori and hepatitis 
viruses (Sassone et al., 2017).  
Breath test followed by gastric biopsy to test 
Helicobacter pylori status is also indicated (Sassone 
et al., 2017).  Cp infection has to be assessed in 
peripheral blood and conjunctival swabs by PCR. 
Imaging analyses include MRI with enhancement 
of the orbit and adjacent structures, total-body CT 
scan or PET/CT. 
Pathology 
OAMZL shares the morphological features of other 
marginal zone lymphomas, characterized by small 
to medium size lymphocytes with centrocytic-like 
or monocytoid features and with a variabile 
evidence of plasma cell differentiation; a minor 
component of intermingled blasts resembling 
centroblasts or immunoblasts is recognized. 
Scattered T-cells and secondary follicles with 
reactive germinal centres accomplish neoplastic B-
cells; follicles can be colonized (sometimes 
mimicking follicular lymphoma) and/or eventually 
destroyed by malignant lymphocytes; these cells 
can specifically infiltrate neighboring epithelia and 
glands to form lymphoepithelial lesions, defined as 
aggregates of ≥3 neoplastic B-cells. In OAMZL, 
lymphoepithelial lesions are detected most 
frequently in the lacrimal gland.  
The classic immunophenotype of OAMZL includes 
expression of B cell markers such as CD20, CD79a 
and PAX5, other molecules like bcl-2 and TCL-1, 
variable expression of CD43, CD11c and IRTA-1. 
Conversely CD5, CD10, CD23, cyclin D1, bcl-6 
and MUM1 are negative, with few exceptions 
(Swerdlow et al., 2016; Sassone et al., 2017). 
Staining for CD23, CD21 or CD35 highlights 
expanded and residual meshwork of follicular 
dendritic cells. Neoplastic cells usually express IgM 
and may also show immunoglobulin light-chain 
restriction. Cytoplasmic Cp-specific 
lipopolysaccharide can be highlighted in the tumor-
associated macrophage cytoplasm by 
immunohistochemistry (Ferreri et al., 2004, 
Ponzoni et al., 2008). Plasma cell differentiation 
may occur and sometimes can be prominent; rarely, 
plasma cells may express IgG4 (Kubota et al., 
2010). Differential diagnosis encompasses non-
neoplastic lymphoproliferations, in particular 
reactive lymphoid hyperplasia and IgG4-related 
disease. Distinction from reactive hyperplasia 
relies, in borderline cases, on the demonstration of 
monotypic immunoglobulin and eventually on 
molecular studies for clonal rearrangement of the 
immunoglobulin heavy chain gene (IgH), detectable 
by PCR in 55% of OAMZL. IgG4-related disease is 
a systemic disease characterized by elevated serum 
IgG4 and infiltration of polytypic IgG4 plasma cells 
associated with reactive lymphoid follicles, 
phlebitis and fibrosis. Clinico-pathological 
correlation is critical for the recognition of this rare 
entity. 
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Figure 1. OAMZL of the conjunctiva showing the massive involvement of the lamina propria by neoplastic cells and the 
infiltration the epithelium above forming typical lymphoepithelial lesions (LELs), more evident with a 8/18 CK staining for 
epithelial cells (inset). Original magnification HE x200, inset x400. 
 
Figure 2. Small to medium size neoplastic cells, with a prominent centrocytic-like appearance, admixed with scattered plasma 
cells and rare larger centroblastic-like cells. Original magnification x400. 
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Figure 3. Neoplastic lymphocytes display a bright and diffuse CD20 staining. Immunostain for Chlamydia lipopolysaccharide 
shows scattered positive macrophages (inset). Original magnification x400; inset, x400. 
 
Figure 4. Anti-CD23 staining for follicular dendritic cells highlights the remnant of a germinal centre (top left of the picture); 
neoplastic cells are CD23 negative. In the inset, the cells show a low proliferative index with a Ki-67 staining. Original 
magnification x200; inset, x200. 
 
Treatment 
There are no uniform guidelines for the 
management of OAMZL, therefore treatment 
strategies remain a matter of debate and linked to 
many patient- and lymphoma-related variables. 
A watchful waiting approach, for example, can be 
useful for asymptomatic elderly patients with 
limited stage disease.  
Radiotherapy, alone or in combination with 
chemotherapy, is the most common therapy. 
Reported outcomes are excellent, with local control 
rates of over 95%, 5 and 10-years DFS rates of 
84,65% and 78,7% and OS of 93,8% and 84,9% 
respectively (Yen et al., 2018). The extension of the 
radiation fields depends on the involved structures. 
The International Lymphoma Radiation Oncology 
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Group suggested a radiation dose of 24-25 Gy 
provided in fractions of 1,5 to 1,8 Gy (Yahalom et 
al., 2015). However, radiation toxicity effects are 
distinct and well-known as well: early 
complications are more frequently represented by 
cutaneous and conjunctival reactions, while long-
term complications are radiation cataract, 
retinopathy, optic neuropathy and xerophthalmia.  
Data on radioimmunotherapy are limited to few, 
small studies, where OAMZL account for a 
minority of the studied cases (Sassone et al., 2017).  
The use of antibiotics relies on the proven 
association with Cp infection. First-line 
doxycycline monotherapy has been demonstrated to 
be well tolerated in a phase II trial study, with ORR 
of 65%, 5-year PFS of 61%  and no significant side 
effects (Ferreri et al., 2012). Antibiotics can also be 
used in Cp negative cases due to its off-target 
effects. Clarithromycin, in particular, displays an 
antitumor and immunomodulatory activity: a phase 
II trial in patients with relapsed/refractory 
OAMZLs achieved good responses with an ORR of 
52% and a 2-year PFS of 56%, respectively (Ferreri 
et al., 2015).  
Chemoimmunotherapy has been proposed as a good 
alternative to radiotherapy both in localized lesions 
and in tumors extended beyond the conjunctiva or 
in bilateral disease (Ma et al., 2017). However, 
definitive data on efficacy of this strategy are still 
lacking, since most trials are retrospective or 
considered a group of indolent lymphomas where 
OAMZLs account only for a minor part of the 
cohort: the most frequently drugs tested in this 
setting are chlorambucil, bendamustin (with or 
without Rituximab), and purine analogs (Sassone et 
al., 2017). A recent phase II clinical trial with 
rituximab, cyclophosphamide, vincristine and 
prednisone (R-CVP) in patients with bilateral, 
limited-stage OAMZL extending beyond-
conjunctiva demonstrated a durable response and 
stressed the possibility and efficacy of a radiation-
free upfront approach (93,9% CR at 2 years and 
90,3% of PFS at 4 years) with severe side effects 
(neutropenia and hepatotoxicity) in a minority of 
cases (12% and 6%, respectively) (Kim et al., 
2017). Data on immunotherapy alone are few, 
mainly focused on larger indolent NHL and extra-
gastric marginal lymphomas categories: a phase II 
trial in 18 patients with relapsed/refractory 
extranodal MZL with Lenalidomide monotherapy 
obtained an ORR of 61% and manageable side-
effects; another study using Bortezomib in patients 
with newly diagnosed or relapsing/refractory 
MALT lymphoma showed good efficacy, with an 
ORR of 80%, but with relevant side effects 
(Kiesewetter et al., 2013; Troch et al., 
Hematologica 2009). Finally, the management of 
the relapsed patients lacks of consensus guidelines 
as well. 
Evolution 
OAMZL is an indolent disease, with a slow 
progression or stable disease without any treatment. 
The median OS time is about 159 months (10-years 
OS 54,7%) in patients treated with radiotherapy in 
combination with chemotherapy,  103 months (10-
years OS 42,6%) in patients treated with 
chemotherapy only, 93 months (10-years OS 
36,8%) in patients treated with radiotherapy only 
and 60 months (32,5%) in patients without any 
treatment (Liu et al., 2018). Local recurrence is 
common, with 5-years relapse free survival rates of 
65%; recurrence in the contralateral orbit is a 
frequent event after radiotherapy. Systemic 
dissemination is a rare event (5-10% of cases) 
(Sassone et al., 2017; Martinet et al., 2003). 
Prognosis 
There is no validated prognostic index for OAMZL. 
Recently, a MALT-IPI score based on the data of 
the IELSG-19 trail and validated on a group of 633 
patients, either with gastric and extra-gastric MALT 
lymphomas, has been introduced.  
The score recognizes three distinct features with the 
greatest prognostic significance in terms of event 
free survival (EFS): age >70 years old, Ann-Arbor 
stage III or IV and elevated lactate dehydrogenase 
level.   
On these grounds, three prognostic groups with 
different 5-years EFS rates have been identified: 
low risk (70%), intermediate risk (56%) and high 
risk (29%), respectively. The MALT-IPI score has 
been demonstrated to be a reliable scoring system 
for identification of patients with aggressive gastric 
and extra-gastric lymphomas which could benefit of 
a different therapeutic approach (Thieblemont et al., 
2017). 
Genetics 
Marginal zone lymphomas share genetic alterations 
and deregulations of some molecular pathways, but 
also site-specific genetic profiles have been 
uncovered in the last years. 
Cytogenetics 
For OAMZLs, data on cytogenetic abnormalities 
are limited: trisomy of chromosome 3 (38-62%) 
and 18 (14-47%) have been observed, and the latter 
has been associated with a higher risk of local 
recurrence (Ferreri et al., 2008. Jung et al., 2017). 
Copy number gain of 6p and 21q and copy number 
loss of 6q and 9p have been described (Takahashi et 
al., 2015. Kwee et al., 2011). T(14;18)(q32;q21) 
IGH/ MALT1 is the most frequent chromosomal 
translocation in OAMZLs (24% of cases); the 
t(11;18) BIRC3 (API2)/MALT1 is very rare  (<3%) 
(Streubel, et al, 2003). 
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Genes involved and 
proteins 
Biased usage of IGHV genes with ongoing somatic 
mutations points out the pathogenetic mechanism of 
antigenic selection (Dagklis et al., 2012).  
The most frequent immunoglobulin rearrangements 
involve IGHV4-34 and IGHV3-23 families and are 
associated with auto-reactive B-cell receptors (Jung 
et al., 2017).  
A number of mutations leading to constitutive 
activation of NF-kB pathway, consequently 
promoting lymphocyte stimulation, proliferation 
and survival, have been detected in about 60% of 
the cases analyzed (Jung et al., 2017).  
Among these, structural variations (deletions or 
mutations) at 6q23.3 involving TNFAIP3 (A20), a 
negative regulator of NF-kB, have been described 
in 54% of cases in OAMZL; structural breakpoints 
(deletions, intra-and inter-chromosomal 
translocations) in the same locus involving IL20RA 
have also been found (Johansson et al., 2016; Jung 
et al., 2017). The transcription regulator and 
chromatin modifier TBL1XR1 is frequently 
mutated (6-18%); loss of function mutations can 
involve the chromatin modifiers CREBBP and 
KMT2D (Moody et al., 2017; Jung et al., 2017; 
Johansson et al., 2016). MYD88 and rare BCL10 
mutations have been described in various reports 
(Cani et al., 2016; Jung et al., 2017). Recurrent 
mutation of TP53 is evidenced even at a low 
frequency. NOTCH1 and NOTCH2 mutations, 
involved in B cell differentiation, have been 
described as well (Johansson et al., 2016; Jung et 
al., 2017). 
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